ETV6/TEL, a member of the ETS family of transcription factors, has been involved in a variety of gene fusions in various neoplasms. One of its fusion partners is NTRK3/TRKC, which encodes the receptor for neurotrophin-3. Although NTRK3 is expressed broadly in neural tissues during the growth and development of the central nervous system, its fusion with TEL has never been reported in central nervous system tumors. We report here a new TEL-NTRK3 fusion in a primitive neuroectodermal tumor (PNET). The patient was five months old when she underwent a resection of a left frontal tumor that was diagnosed as a benign desmoplastic infantile ganglioglioma. Three months later she had another resection for the recurrent tumor, which was diagnosed as a highly malignant PNET. G-banding karyotype analysis showed 46, XX in both tumors, but spectral karyotyping revealed a single near-tetraploid cell in the first tumor with a t(12; 15)(p13; q25) translocation and the same translocation in all metaphases in the PNET. Subsequent fluorescence in situ hybridization analysis using a TEL probe revealed the translocation of the TEL gene to the der(15) chromosome. Based on a similar translocation previously described in infantile fibrosarcoma, congenital mesoblastic nephroma and acute myeloid leukemia involving the TEL and NTRK3 genes, we used the polymerase chain reaction with reverse transcription, with primers flanking the coding sequences of TEL and NTRK3, to detect a chimeric message of 1.6 kilobases. We located the breakpoint at the end of exon 4 of TEL in frame with exon 12 of NTRK3. This results in a unique TEL-NTRK3 fusion transcript with the helix-loop-helix dimerization domain of TEL fused to the protein tyrosine kinase domain of NTRK3. Since t(12; 15) is the only structural chromosome aberration in this case and a similar TEL-NTRK3 fusion product has been used to transform NIH 3T3 cells, we propose that the TEL-NTRK3 fusion may have contributed to the cellular transformation and progression of this tumor.
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Adjuvant tamoxifen therapy is effective in reducing the risk of recurrence and death in patients with estrogen-receptor-positive breast cancer. However, the development of acquired resistance to tamoxifen limits its clinical effectiveness. To determine the effects of tamoxifen on breast cancer cells, long-term cultures of the breast cancer MCF-7 cell line, treated with tamoxifen, were established. Gene expression profiles of tamoxifen-treated and untreated MCF-7 cells were characterized using the Clontech Atlas human cancer 1.2 array, representing 1,176 genes. RNA was extracted from tamoxifen-sensitive cells 4 days and 6 weeks after commencement of treatment with tamoxifen, as well as from untreated MCF-7 cells at the same time points. Only gene expression differences greater than twofold were considered. At 4 days, 13 genes were found to be overexpressed and 2 genes were underexpressed in the tamoxifen-treated MCF-7 cells compared with the untreated MCF-7 cells. In the tamoxifen-treated MCF-7 cells harvested at 6 weeks, 16 genes were overexpressed and 5 genes were underexpressed compared with the treated cells harvested at 4 days. Wnt-5a, disheveled homologue 1, cyclin kinase inhibitor p19INK4D and the signaling lymphocytic activation molecule were overexpressed in both of the comparisons. Gene expression profiling is useful for the rapid identification of genes differentially expressed during tamoxifen treatment.
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Proteomics: new way to to determine possible biological effects of mobile phone radiation
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Despite years of research, the question of whether exposure to radiofrequencymodulated electromagnetic fields (RF-EMF) generated by mobile phones affects human health remains unsolved. We obtained a comprehensive overview of the possible extent of cellular response to RF-EMF irradiation by determining the total cellular changes in protein expression and in protein phosphorylation that occur in response to RF-EMF exposure under athermal conditions. As a model we used human endothelial cell line EA.hy926. Cells were exposed for one hour to a 900-MHz GSM signal. Immediately following exposure we harvested cells and extracted and separated proteins using two-dimensional electrophoresis. To determine changes in protein phosphorylation, 32 P was present in the cultures during the exposure period. Using Bio-Rad's PDQUEST 6.1.0 software we identified over 1,200 proteins in two-dimensional gels (10 × 20 cm). A large number of protein spots changed expression following irradiation. In control cells we detected over 180 phosphoproteins. RF-EMF exposure has generated a large number of newly phosphorylated proteins that were not present in controls. Among the proteins with altered phosphorylation levels were shock proteins, such as hsp27. Thus the expression and phosphorylation of a large number of proteins isolated from EA.hy926 cells seems to be altered by short RF-EMF exposure, suggesting that cells mount a vigorous response to RF-EMF stress. However, whether the observed stress can cause long-lasting physiological effects remains to be determined. [38] Identification and characterization of a 19q12 amplicon in esophageal adenocarcinomas using two-dimensional genomic scanning and amplification mapping of sequence tagged sites
Lin, Lin
We have used a two-dimensional restriction landmark genomic scanning technique to identify gene amplification events in esophageal adenocarcinomas. We cloned a multicopy DNA fragment from a tumor two-dimensional gel and confirmed genomic amplification encompassing this fragment by Southern blot analysis. The corresponding DNA sequence was searched by BLAST, which allowed the use of an electronic polymerase chain reaction to map the amplicon to 19q12. We then characterized the amplicon using sequence-tagged site amplification mapping, an approach recently developed in our laboratory. DNAs from 65 esophageal and 11 gastric cardia adenocarcinomas and their normal controls were investigated using 11 sequence-tagged site markers neighboring the cloned fragment. The amplicon, spanning 8 centimorgans, was narrowed to a minimal region of 0.8 cM, which includes the cyclin E gene. We assayed 14 expressed sequence tags covering the minimal region for gene overexpression. Both DNA amplification and messenger RNA overexpression were observed in 7 of the 14 expressed sequence tags selected. Among them, cyclin E demonstrated the highest frequency of gene amplification and overexpression in the tumors examined. After analyzing the sequencetagged site amplification patterns within BAC contig sequences located at 19q12 in the databases, we further defined the core amplified domain to a region 300 kilobases long. We observed amplification of 19q12 in 13.8% of esophageal adenocarcinomas. Our study is the first to map the core amplified domain of the 19q12 amplicon physically to a 300-kb region, and the data indicate that cyclin E is the probable target gene selected by the amplification event at 19q12.
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